Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Efficacy Study of HS-10380 in Patients With Schizophrenia [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/Phase 2 clinical trial update for HS-10380 in schizophrenia focusing on safety, tolerability, pharmacokinetics, and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• HS-10380

Snippet

Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. | Conditions: Schizophrenia | Phase 1, Phase 2 | Status: UNKNOWN